C₂₂H₃₇NO₂ · 347.53 g/mol
N-arachidonoylethanolamine
The body's natural THC — endocannabinoid, CB1 agonist, bliss molecule
Anandamide (AEA) is an endogenous cannabinoid — a molecule produced naturally by the human body that activates the same receptors as THC. Its name derives from the Sanskrit word 'ananda' meaning bliss or happiness. Discovered in 1992 by Raphael Mechoulam and colleagues, anandamide was the first endocannabinoid identified and remains the most studied. Unlike THC, anandamide is rapidly degraded by the enzyme FAAH (fatty acid amide hydrolase), producing brief, localized effects. Understanding anandamide's biology has opened new therapeutic strategies including FAAH inhibitors as non-intoxicating analgesics and anxiolytics.
Studies Indexed
4,200+
Half-Life
Minutes (rapidly degraded by FAAH)
Primary Receptors
CB1 (partial agonist, Ki ~89 nM), CB2 (partial agonist), TRPV1, GPR55, GPR18, PPARα
Last Updated
June 2026
Anandamide is synthesized on-demand from N-arachidonoyl phosphatidylethanolamine (NAPE) in cell membranes via NAPE-phospholipase D. Unlike classical neurotransmitters, it is not stored in vesicles but produced and released immediately when needed. Anandamide acts as a retrograde messenger — released from postsynaptic neurons, it travels backward to inhibit presynaptic neurotransmitter release via CB1 receptors. This retrograde signaling is the primary mechanism by which the endocannabinoid system modulates synaptic plasticity. Anandamide is rapidly inactivated by FAAH, which explains why it produces more subtle, localized effects than THC. Anandamide also activates TRPV1 channels (the capsaicin receptor), GPR55, and PPARα, giving it a broader pharmacological profile than simple CB1 agonism. The 'runner's high' — the euphoria experienced during sustained aerobic exercise — has been partially attributed to anandamide release, though recent research suggests endorphins and endocannabinoids both contribute. FAAH inhibitors, which prevent anandamide degradation and thus enhance its effects, are being developed as non-intoxicating alternatives to direct CB1 agonists for pain and anxiety.
Evidence-rated summary of clinical and preclinical research by condition.
Anandamide mediates endogenous pain suppression via CB1 receptors in the periaqueductal gray and spinal cord. FAAH inhibitors that increase anandamide levels produce analgesia in animal models without THC-like psychoactivity.
Anandamide in the amygdala and prefrontal cortex modulates fear and anxiety responses. Stress depletes anandamide levels; FAAH inhibitors restore anandamide tone and reduce anxiety in animal models. Human FAAH inhibitor trials are ongoing.
Anandamide levels increase significantly after aerobic exercise and correlate with mood improvements. CB1 blockade reduces exercise-induced euphoria in mice, implicating anandamide in the runner's high.
Anandamide plays a critical role in embryo implantation, with uterine anandamide levels precisely regulated during the implantation window. Disruption of anandamide signaling impairs fertility in animal models.
Anandamide has neuroprotective effects in models of ischemia, traumatic brain injury, and neurodegeneration via CB1 and TRPV1 activation. FAAH inhibition enhances these effects.
Peer-reviewed research with DOI links
Devane WA, Hanus L, Breuer A, et al.
Science
Landmark paper reporting the isolation and characterization of anandamide from porcine brain, identifying the first endogenous cannabinoid ligand and establishing the endocannabinoid system.
DOI: 10.1126/science.1470919Jayamanne A, Greenwood R, Mitchell VA, et al.
British Journal of Pharmacology
Demonstrated that FAAH inhibition increases anandamide levels and produces analgesia in rat models of neuroinflammatory pain, supporting FAAH as a therapeutic target.
DOI: 10.1038/sj.bjp.0706510Zou S, Kumar U
International Journal of Molecular Sciences
Comprehensive review of endocannabinoid system signaling, covering anandamide and 2-AG synthesis, degradation, receptor pharmacology, and physiological functions.
DOI: 10.3390/ijms19030833Known interactions with pharmaceutical drugs. Consult a healthcare provider before combining. Full interactions database →
| Drug / Class | Severity | Mechanism | Clinical Effect |
|---|---|---|---|
| FAAH inhibitors (BIA 10-2474, PF-04457845) | major | Prevent anandamide degradation, dramatically increasing AEA levels | FAAH inhibitors can produce CB1-mediated effects; BIA 10-2474 caused serious neurological adverse events in a 2016 Phase I trial — FAAH inhibitor development requires extreme caution |
| CBD | moderate | CBD inhibits FAAH and anandamide reuptake, increasing AEA levels | CBD may enhance anandamide signaling; this may contribute to CBD's anxiolytic effects |
| THC | moderate | THC competes with anandamide at CB1 receptors and may downregulate FAAH | Chronic THC use may alter endogenous anandamide tone; withdrawal may involve anandamide deficiency |
| Acetaminophen (paracetamol) | minor | Acetaminophen is metabolized to AM404, which inhibits anandamide reuptake | Acetaminophen's analgesic effects are partially mediated by enhanced anandamide signaling — a novel mechanism |
Critical questions that remain unanswered in the current literature — representing the frontier of Anandamide (AEA) research.
Explore the clinical and preclinical evidence for Anandamide (AEA) across these therapeutic areas.
